Axa Framlington Biotech Fund

Select share classes

AXA Framlington Biotech Fund Z INC

Category Sector Equity Biotechnology


star-filledstar-filledstar-filledstar-filledstar-filled
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price

171.90p

arrow-down-2.50p (-1.43%)

Fund Code

FMBZI

BRJZVL2

GB00BRJZVL27

Prices updated as at 25 Apr 2024
|
Prices in GBX

Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.

Fund statusOpen
Fund typeUnit Trust
Fund managerLinden Thomson, Cinney Zhang
189.7
151.3
Fund comparative indexNASDAQ Biotechnology TR USD
Specialist
-
0.80
0.37
0.00
Sector Equity Biotechnology
No
Fund providerAXA Investment Managers UK Ltd
Share class launch date19 Jan 2015
£438.77m
-
0.00
-
Semi-Annually
Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.